BioCentury
ARTICLE | Clinical News

BioTime reports Phase I/IIa data for dry AMD candidate

December 1, 2017 9:50 PM UTC

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported data from 6 evaluable patients with dry age-related macular degeneration (AMD) in a Phase I/IIa trial showing that subretinal transplantation of 50,000 or 200,000 OpRegen cells was well tolerated with no treatment-related systemic serious adverse events reported. Additionally, OpRegen led to stable best corrected visual acuity up to 15 months. New or worsening epiretinal membrane formation was reported in 5 patients.

Data were presented at the American Academy of Opthalmology meeting in New Orleans...

BCIQ Company Profiles

Lineage Cell Therapeutics Inc.